Improvement of stress LVEF rather than rest LVEF after coronary revascularisation in patients with ischaemic cardiomyopathy and viable myocardium

V Rizzello, D Poldermans, E Biagini, A F L Schinkel, R van Domburg, A Elhendy, E C Vourvouri, M Bountioukos, A Lombardo, B Krenning, J R T C Roelandt and J J Bax

*Heart* 2005;91:319-323
doi:10.1136/hrt.2004.037119

Updated information and services can be found at:
http://heart.bmjjournals.com/cgi/content/full/91/3/319

These include:

**References**
This article cites 28 articles, 18 of which can be accessed free at:
http://heart.bmjjournals.com/cgi/content/full/91/3/319#BIBL

**Rapid responses**
You can respond to this article at:
http://heart.bmjjournals.com/cgi/eletter-submit/91/3/319

**Email alerting service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Topic collections**
Articles on similar topics can be found in the following collections
- Cardiomyopathy (295 articles)
- Radiological diagnosis (598 articles)
- Ischemic heart disease (2079 articles)
- Vascular Surgery (344 articles)

**Notes**

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to *Heart* go to:
http://www.bmjjournals.com/subscriptions/
Improvement of stress LVEF rather than rest LVEF after coronary revascularisation in patients with ischaemic cardiomyopathy and viable myocardium

V Rizzello, D Poldermans, E Biagini, A F L Schinkel, R van Domburg, A Elhendy, E C Vourvouri, M Bountioukos, A Lombardo, B Krenning, J R T C Roelandt, J J Bax

Objective: To evaluate prospectively the response of left ventricular ejection fraction (LVEF) to high dose dobutamine infusion in patients showing substantial viability, with and without improved resting LVEF after revascularisation.

Methods: Before and 9–12 months after revascularisation, 50 patients with ischaemic cardiomyopathy (LVEF 32 (8)% and substantial myocardial viability (≥ 4 viable segments) underwent radionuclide ventriculography and dobutamine stress echocardiography. Patients were divided into group 1, patients with, and group 2, patients without significant improvement in resting LVEF (≥ 5% by radionuclide ventriculography) after revascularisation. The response of LVEF during dobutamine stress echocardiography was compared in these two groups.

Results: Groups 1 and 2 were comparable in baseline characteristics, resting LVEF, and number of viable segments (mean (SD) 7 (4) v 6 (2), not significant). After revascularisation, the LVEF response during dobutamine stress echocardiography improved significantly in both groups (group 1, 34 (10)% to 56 (8)%; group 2, 32 (10)% to 46 (11)%; both p < 0.001). Interestingly, although resting LVEF did not improve in group 2, peak stress LVEF after revascularisation did (p < 0.001). Group 1 patients had, however, a greater increase in peak stress LVEF (group 1, 22 (10)%; group 2, 13 (9)%; p < 0.01). New York Heart Association and Canadian Cardiovascular Society classes decreased in both groups.

Conclusions: Although patients with viable myocardium did not always have improved rest LVEF after revascularisation, peak stress LVEF improved. Assessment of improvement of resting function may not be the ideal end point to evaluate successful revascularisation.
Study protocol
The study protocol was prospectively designed to evaluate the response of LVEF to dobutamine challenge before and after revascularisation. DSE was performed one week before and 9–12 months after revascularisation. Radionuclide ventriculography (RNV) was also performed before and 9–12 months after revascularisation to assess improvement of resting LVEF by an independent technique. β-Blockers were not discontinued before DSE and RNV. An improvement in LVEF >5% after revascularisation was considered clinically significant. According to the presence or absence of significant improvement in resting LVEF after revascularisation, the patients were divided into two groups: group 1, patients with improved resting LVEF; and group 2, patients without improved resting LVEF. Next, the response of LVEF during dobutamine stress before and after revascularisation was compared in these two groups. In addition, heart failure symptoms and angina score were evaluated during the study period. The local ethics committee approved the protocol and all patients gave informed consent to participate in the study.

Assessment of LVEF
Before and 9–12 months after revascularisation, RNV was performed to assess LVEF improvement by an independent technique. RNV was performed at rest with the patient in the supine position after the administration of 740 MBq of 99mTc-technetium. Images were acquired with a small field of view gamma camera (Orbiter; Siemens Corp, Iselin, New Jersey, USA) oriented in the 45° left anterior oblique position with a 5–10° caudal tilt. LVEF was calculated from the 45° left anterior oblique view by an automated technique. An improvement in LVEF >5% after revascularisation was considered clinically significant.

Dobutamine stress echocardiography
All echocardiograms were recorded by commercially available equipment (Sonos 5500; Hewlett Packard, Philips Medical Systems, Eindhoven, the Netherlands) with a second harmonic 1.8–3.6 MHz transducer to optimise endocardial border visualisation. Standard parasternal and apical views of the LV were obtained at rest and at the end of each step of dobutamine infusion. Dobutamine was administered intravenously as previously described, starting at a dose of 5 μg/kg/min for five minutes, followed by 10 μg/kg/min for five minutes. Subsequently, incremental dobutamine doses of 10 μg/kg/min were given at three minute intervals up to a maximum dose of 40 μg/kg/min. Atropine (up to 2 mg) was administered intravenously if the test end point was not reached. Blood pressure, cardiac rhythm, and ST segment sloping were continuously monitored.

Test end points were achievement of target heart rate, extensive new wall motion abnormalities, horizontal or down sloping ST segment depression (>2 mm compared with baseline), severe angina, systolic blood pressure fall >40 mm Hg, blood pressure >240/120 mm Hg, and significant supraventricular or ventricular arrhythmia. Metoprolol (1–5 mg intravenously) was available to reverse significant supraventricular or ventricular arrhythmia. Metoprolol (1–5 mg intravenously) was available to reverse the effects of dobutamine. Severely dysfunctional segments (including severe hypokinesia, akinesia, and dyskinesia) were evaluated for the presence of viability. Segments with a sustained improvement in wall motion up to high dose dobutamine and segments with a biphasic response or worsening of wall motion during DSE were considered viable. Segments with unchanged wall motion and segments with akinesia becoming dyskinesia were considered non-viable. A substantial amount of viable myocardium was defined as the presence of ≥4 viable segments. This definition is based on previous work with receiver operating characteristic curve analysis showing that recovery of function may be predicted in the presence of ≥4 viable segments.

Assessment of response in LVEF to high dose dobutamine
The study results were analysed off line. LV volumes were measured at rest and during low and high dose dobutamine

---

Table 1  Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Group 1: improvers (n = 26)</th>
<th>Group 2: non-improvers (n = 24)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Men</strong></td>
<td>22 (85%)</td>
<td>18 (75%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>62 (12)</td>
<td>60 (12)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Previous MI</strong></td>
<td>24 (92%)</td>
<td>24 (100%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Q wave MI</strong></td>
<td>20 (83%)</td>
<td>21 (87%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Anterior MI</strong></td>
<td>14 (54%)</td>
<td>15 (62%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>NYHA class</strong></td>
<td>3.15 (0.8)</td>
<td>2.96 (0.7)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>CCS class</strong></td>
<td>2.57 (0.7)</td>
<td>2.67 (0.6)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Stenotic vessels</strong></td>
<td>2.4 (0.7)</td>
<td>2.7 (0.4)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Smoking</strong></td>
<td>12 (46%)</td>
<td>14 (54%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td>22 (85%)</td>
<td>21 (87%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Hypercholesterolaemia</strong></td>
<td>16 (61%)</td>
<td>13 (54%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Family history of CAD</strong></td>
<td>13 (50%)</td>
<td>16 (67%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Diabetes mellitus</strong></td>
<td>1 (5%)</td>
<td>2 (8%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Lipid lowering drugs</strong></td>
<td>13 (50%)</td>
<td>10 (42%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>ACE inhibitors</strong></td>
<td>17 (65%)</td>
<td>19 (79%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Nitrates</strong></td>
<td>22 (85%)</td>
<td>19 (79%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>β Blockers</strong></td>
<td>16 (61%)</td>
<td>16 (67%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Diuretics</strong></td>
<td>12 (46%)</td>
<td>16 (67%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Digoxin</strong></td>
<td>4 (15%)</td>
<td>7 (29%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Aspirin/anticoagulant</strong></td>
<td>26 (100%)</td>
<td>22 (92%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>LVEF (%)</strong></td>
<td>33 (10)*</td>
<td>32 (7)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>LV end diastolic volume (ml)</strong></td>
<td>160 (59)</td>
<td>194 (37)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td><strong>LV end systolic volume (ml)</strong></td>
<td>105 (49)</td>
<td>135 (37)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td><strong>LV sphericity index</strong></td>
<td>0.58 (0.09)</td>
<td>0.61 (0.11)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Data are mean (SD) or number (%). *Assessed by radionuclide ventriculography. †Derived by the ratio of left ventricular (LV) short to long axis dimensions in the apical four chamber view. ACE, angiotensin converting enzyme; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NS, not significant; NYHA, New York Heart Association.
infusion with the biplane disk method, a modification of Simpson's rule. Subsequently, the LVEF at baseline and during low and high dose dobutamine were calculated by using the following equation: [end diastolic volume – end systolic volume]/end diastolic volume. All measurements were undertaken by an independent, experienced reader blinded to the clinical data and time of the study. Interobserver and intraobserver variability for LVEF calculation were reported previously (3.3% and 5.3% respectively). Assessment of functional status
Before and after revascularisation, an independent physician blinded to all data conducted structured clinical interviews to assess the functional status according to the NYHA (for symptoms of heart failure) and the CCS (for angina) criteria.

Statistical analysis
Continuous data are expressed as mean (SD) and dichotomous data as proportions. Continuous data were compared by Student’s t test for paired and unpaired samples and two way analysis of variance to evaluate differences across time and between different groups, as indicated. Proportions were compared by χ² analysis. For all tests, p < 0.05 was considered significant.

RESULTS
Improvement of resting LVEF after revascularisation
After revascularisation, resting LVEF improved significantly (> 5%) in 26 patients (group 1) whereas it failed to improve in 24 patients (group 2). In particular, resting LVEF increased on average from 33 (10)% to 43 (10)% (p < 0.001) in group 1, whereas a slight but significant decrease was observed in group 2 (from 32 (7)% to 30 (7)%; p < 0.001). Baseline clinical characteristics of patients with (group 1) and without (group 2) improved resting LVEF were comparable (table 1).

Resting LVEF by RNV and LV sphericity index were similar in the two groups (table 1), whereas LV end diastolic and end systolic volumes were significantly larger in group 2 (table 1). In addition, group 1 and group 2 were comparable in the extent of viable myocardium (7.4 (4) and 6.0 (2) segments, not significant) but group 2 patients had a larger extent of scar tissue (6.1 (2.3) v 3.7 (3.0), p < 0.05).

DSE before and after revascularisation
The haemodynamic response during DSE was similar before and after revascularisation in the two groups. In particular, the peak rate–pressure product was 16.270 (2.895) v 16.057 (2.902) (not significant) in group 1 and 16.897 (3.226) v 16.208 (3.225) (not significant) in group 2. The proportion of patients who reached 85% of the age predicted target heart rate was also similar before and after revascularisation (98% v 92%, respectively, not significant). Before and after revascularisation, medication (including β blockers) was comparable; only the use of nitrates was significantly reduced postoperatively (85% v 19%, p < 0.001, in group 1 and 79% v 25%, p < 0.001, in group 2).

Table 2 LVEF (%) during dobutamine stress echocardiography

<table>
<thead>
<tr>
<th></th>
<th>Before revascularisation*</th>
<th>After revascularisation**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rest LD Peak p Value</td>
<td>Rest LD Peak p Value p Value</td>
</tr>
<tr>
<td>Group 1</td>
<td>34 (8) 46 (11) 34 (10) &lt;0.001</td>
<td>43 (9) 54 (8) 56 (8) &lt;0.001 &lt;0.001</td>
</tr>
<tr>
<td>Group 2</td>
<td>31 (8) 41 (9) 32 (10) &lt;0.001</td>
<td>31 (7) 44 (10) 46 (11) &lt;0.001 &lt;0.001</td>
</tr>
</tbody>
</table>

*p = 0.03 group 1 v group 2; ** p < 0.001 group 1 v group 2; † p value before versus after revascularisation for the pattern of response during dobutamine stress echocardiography. LD, low dose.
patients with substantial viable myocardium. However, other improvement in LVEF despite the presence of viable improved LVEF. Also advanced LV remodelling may limit the extent of scar tissue was larger in the patients who did not have viability is needed to obtain functional improvement. 4–7 16 Bax methods to assess viability are measured. 8 Initial studies improvement of LV function has been combined low and high doses of dobutamine infusion in these regions after revascularisation. Expression of LVEF after coronary revascularisation (representing cardiac stress performance) have not been reported thus far.

In the present study, we evaluated the response of LVEF to combined low and high dose stress tests. The study by Lombardo and colleagues,7 resting function did not improve in 48% of patients with substantial viability, peak stress LVEF did not improve compared with before revascularisation.

Discussion

Improvement of LVEF after coronary revascularisation has been described in variable proportions of patients with ischaemic cardiomyopathy and substantial myocardial viability. The findings in the present study showed that, although resting LVEF did not improve in 48% of patients with substantial viability, peak stress LVEF did not improve compared with before revascularisation.

Beneficial effect of coronary revascularisation on resting LV function

Postoperative improvement of LV function has been considered the benchmark against which the preoperative methods to assess viability are measured.9 Initial studies showed that regional LV function improved after revascularisation, whereas in more recent studies global LV function improved.6 It has become clear that substantial myocardial viability is needed to obtain functional improvement.4–6 Bax and colleagues showed that LVEF improved in 82% of patients with substantial viable myocardium. However, other studies have shown that resting LVEF does not always improve after revascularisation.7–11 In the present study, only patients with a substantial amount of viable myocardium (at least 25% of the LV) were included. After revascularisation, however, only 52% of the patients had significantly improved resting LVEF. Similarly, in the study by Pasquet and colleagues7 resting LVEF after revascularisation improved significantly in only 47% of patients shown by low and high dose DSE and nuclear imaging to have extensive viability.1 These varying percentages of patients experiencing recovery in LVEF after revascularisation are likely to be related to different characteristics of study populations. In particular, besides myocardial viability, additional factors may play a part in determining functional recovery after coronary revascularisation. It has been shown that the presence of extensive scar tissue may prohibit the increase of LVEF after revascularisation, despite viable myocardium.12–14 Accordingly, in the present study the extent of scar tissue was larger in the patients who did not have improved LVEF. Also advanced LV remodelling may limit the improvement in LVEF despite the presence of viable myocardium.15–17 In the present study, baseline LV end diastolic and end systolic volumes were significantly larger in patients who did not have improved LVEF after revascularisation. Finally, delayed revascularisation and graft occlusion or restenosis after intervention may prevent functional recovery of viable myocardium.21–22

Effect of coronary revascularisation on LVEF response to dobutamine challenge

In the present study, resting LVEF improved in only 52% of patients, despite the presence of substantial viability. It has been suggested that, although resting function does not improve, the contractile reserve may increase during inotropic challenge after revascularisation.4–6 In the study by Lombardo and colleagues,7 resting function did not improve after revascularisation in 57% of the dysfunctional regions shown by DSE to be viable before revascularisation. However, the contractile reserve was observed to increase during low dose dobutamine infusion in these regions after revascularisation. Elhendy and colleagues10 showed that LVEF during low dose dobutamine challenge increased even in patients who did not have improved resting LVEF after revascularisation. The responses of LVEF to high dose dobutamine after revascularisation (representing cardiac stress performance) have not been reported thus far.

In the present study, we evaluated the response of LVEF to combined low and high dose stress tests. The study by Lombardo and colleagues7 resting function did not improve in 48% of patients with viable myocardium, peak stress LVEF did improve. Therefore, postoperative DSE identified additional patients who benefited from revascularisation in terms of global stress function, even though resting function did not improve. Although previous studies have shown that additional benefits (besides recovery of resting function) may be present after revascularisation, the present study uniquely showed that peak LVEF improved in patients without improved resting LVEF.

In a previous study that used a comparable low and high dose DSE protocol, Afridi and colleagues23 showed that the wall motion score index at peak stress also improved in patients without improved resting function (defined as an improvement of the wall motion score by $\geq 2$ grades in at least two contiguous segments). The findings in the present study are in line with this observation and show the beneficial effect of revascularisation on cardiac stress performance. Relief of ischaemia by restoration of the coronary flow reserve may be the mechanism responsible for maintaining the contractile function up to peak stress. This hypothesis is supported by data from Elhendy and colleagues10 showing that the ischaemic score according to thallium-201 imaging decreased significantly after revascularisation in both patients with and patients without improved resting LVEF. Also, in the study by Afridi and colleagues,23 the majority of the improvement in stress wall motion score occurred in patients with evidence of ischaemia before revascularisation.

In line with previous studies, the observations in the present study suggest that assessment of resting LVEF after revascularisation may not be the ideal end point to evaluate the success of coronary revascularisation. Assessment of LVEF response to low and high dose DSE after revascularisation may be a more appropriate strategy to evaluate fully the benefit of revascularisation. The improvement of LVEF up to high dose dobutamine suggests the presence of a sustained contractile reserve and the absence of significant ischaemia. Preservation of contractile reserve and relief of ischaemia may be important in improving the prognosis of patients with

![Figure 2 Bar graph showing the effect of revascularisation on heart failure and angina symptoms. After revascularisation, New York Heart Association (NYHA) and Canadian Cardiovascular Society (CCS) classes improved significantly both in patients with (group 1) and in patients without (group 2) improvement in resting LVEF.](heart.bmjournals.com/content/10/2005/111007.fig2)

![Figure 2](heart.bmjournals.com/content/10/2005/111007.fig2)
ischaemic cardiomyopathy by preventing LV remodelling and ischaemia related arrhythmias.24

Implications of improved stress function

Post-revascularisation improvement of heart failure symptoms has been shown to relate to the presence of viable myocardium before revascularisation.1 25 26 This was also observed in the current study. It is conceivable that improved stress LVEF may relate to improved functional class. It has been also shown that patients with myocardial viability who underwent revascularisation had a better prognosis than did medically treated patients.27 28 This superior prognosis may also (in part) be related to the improvement of stress LVEF (reflecting absence of ischaemia). Further studies are needed to clarify this issue.

Limitations

Coronary angiography was not repeated after revascularisation, nor was perfusion imaging performed. Therefore, failure of resting LVEF to improve because of graft closure or restenosis after intervention cannot be excluded. However, none of the patients had an ischaemic response to DSE after revascularisation. The study population is relatively small. Further studies with more patients are needed to clarify the prognostic implications of these findings.

Conclusion

Assessment of resting LV function has been used as the yardstick to evaluate the success of coronary revascularisation in patients with ischaemic cardiomyopathy and viable myocardium. The findings in the present study showed that assessment of resting LVEF may underestimate the benefit of revascularisation, since stress LVEF may improve even in patients without improved resting LVEF. Moreover, the improvement in stress LVEF was accompanied by improved functional status.

Authors’ affiliations

D Poldermans, E Biagini, A F L Schinkel, R van Domburg, A Elhendy, E C Vourvouri, M Bountioukos, B Krenning, J R T C Roelandt, Department of Cardiology, Thoraxcentre, Erasmus MC, Rotterdam, the Netherlands

V Rizzello, A Lombardo, Department of Cardiology, The Catholic University of the Sacred Heart, Rome, Italy

J J Bax, Department of Cardiology, Leiden University Medical Centre, Leiden, the Netherlands

REFERENCES


24 Kaul S. There may be more to myocardial viability than meets the eye. Circulation 1995;92:2790–3.


